Insulet Corporation (PODD)

$167.27

+2.85

(+1.73%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Insulet Corporation

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 358.1M → 509.8M (in $), with an average increase of 11.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 7 quarters, -35.0M → 103.3M (in $), with an average increase of 140.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 33.1% return, outperforming this stock by 81.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 59.2% return, outperforming this stock by 103.6%

Performance

  • $164.61
    $168.82
    $167.27
    downward going graph

    1.59%

    Downside

    Day's Volatility :2.49%

    Upside

    0.92%

    downward going graph
  • $125.82
    $335.91
    $167.27
    downward going graph

    24.78%

    Downside

    52 Weeks Volatility :62.54%

    Upside

    50.2%

    downward going graph

Returns

PeriodInsulet CorporationSector (Health Care)S&P500
3 Months
-19.52%
-0.4%
3.0%
6 Months
11.85%
9.6%
18.8%
1 Year
-48.42%
3.9%
21.2%
3 Years
-44.36%
12.8%
19.9%

Highlights

Market Capitalization
11.6B
Book Value
$10.48
Earnings Per Share (EPS)
2.94
PE Ratio
56.55
PEG Ratio
3.15
Wall Street Target Price
236.83
Profit Margin
12.16%
Operating Margin TTM
26.07%
Return On Assets TTM
6.09%
Return On Equity TTM
34.13%
Revenue TTM
1.7B
Revenue Per Share TTM
24.33
Quarterly Revenue Growth YOY
37.9%
Gross Profit TTM
805.6M
EBITDA
308.6M
Diluted Eps TTM
2.94
Quarterly Earnings Growth YOY
5.04
EPS Estimate Current Year
2.99
EPS Estimate Next Year
3.78
EPS Estimate Current Quarter
0.66
EPS Estimate Next Quarter
0.43

Analyst Recommendation

Buy
    74%Buy
    25%Hold
    0
    0%Sell
Based on 27 Wall street analysts offering stock ratings for Insulet Corporation(by analysts ranked 0 to 5 stars)
Based on 27 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
18
17
Hold
7
8
9
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 41.59%

Current $167.27
Target $236.83

Company Financials

FY18Y/Y Change
Revenue
563.8M
↑ 21.57%
Net Income
3.3M
↓ 112.27%
Net Profit Margin
0.58%
↑ 6.37%
FY19Y/Y Change
Revenue
738.2M
↑ 30.93%
Net Income
11.6M
↑ 252.37%
Net Profit Margin
1.57%
↑ 0.99%
FY20Y/Y Change
Revenue
904.4M
↑ 22.51%
Net Income
6.8M
↓ 41.38%
Net Profit Margin
0.75%
↓ 0.82%
FY21Y/Y Change
Revenue
1.1B
↑ 21.49%
Net Income
16.8M
↑ 147.06%
Net Profit Margin
1.53%
↑ 0.78%
FY22Y/Y Change
Revenue
1.3B
↑ 18.79%
Net Income
4.6M
↓ 72.62%
Net Profit Margin
0.35%
↓ 1.18%
FY23Y/Y Change
Revenue
1.7B
↑ 30.02%
Net Income
206.3M
↑ 4384.78%
Net Profit Margin
12.16%
↑ 11.81%
Q3 FY22Q/Q Change
Revenue
340.8M
↑ 13.83%
Net Income
-5.2M
↓ 85.14%
Net Profit Margin
-1.53%
↑ 10.16%
Q4 FY22Q/Q Change
Revenue
369.7M
↑ 8.48%
Net Income
17.0M
↓ 426.92%
Net Profit Margin
4.6%
↑ 6.13%
Q1 FY23Q/Q Change
Revenue
358.1M
↓ 3.14%
Net Income
23.8M
↑ 40.0%
Net Profit Margin
6.65%
↑ 2.05%
Q2 FY23Q/Q Change
Revenue
396.5M
↑ 10.72%
Net Income
27.3M
↑ 14.71%
Net Profit Margin
6.89%
↑ 0.24%
Q3 FY23Q/Q Change
Revenue
432.7M
↑ 9.13%
Net Income
51.9M
↑ 90.11%
Net Profit Margin
11.99%
↑ 5.1%
Q4 FY23Q/Q Change
Revenue
509.8M
↑ 17.82%
Net Income
103.3M
↑ 99.04%
Net Profit Margin
20.26%
↑ 8.27%
FY18Y/Y Change
Total Assets
928.7M
↑ 13.71%
Total Liabilities
716.6M
↑ 8.87%
FY19Y/Y Change
Total Assets
1.1B
↑ 23.06%
Total Liabilities
1.1B
↑ 48.89%
FY20Y/Y Change
Total Assets
1.9B
↑ 63.87%
Total Liabilities
1.3B
↑ 18.96%
FY21Y/Y Change
Total Assets
2.0B
↑ 9.39%
Total Liabilities
1.5B
↑ 17.58%
FY22Y/Y Change
Total Assets
2.3B
↑ 9.87%
Total Liabilities
1.8B
↑ 18.91%
FY23Y/Y Change
Total Assets
2.6B
↑ 14.97%
Total Liabilities
1.9B
↑ 4.55%
Q3 FY22Q/Q Change
Total Assets
2.2B
↑ 2.48%
Total Liabilities
1.7B
↑ 2.77%
Q4 FY22Q/Q Change
Total Assets
2.3B
↑ 3.92%
Total Liabilities
1.8B
↑ 2.1%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 1.69%
Total Liabilities
1.8B
↑ 0.65%
Q2 FY23Q/Q Change
Total Assets
2.4B
↑ 4.22%
Total Liabilities
1.8B
↑ 2.55%
Q3 FY23Q/Q Change
Total Assets
2.5B
↑ 3.43%
Total Liabilities
1.9B
↑ 1.54%
Q4 FY23Q/Q Change
Total Assets
2.6B
↑ 4.88%
Total Liabilities
1.9B
↓ 0.25%
FY18Y/Y Change
Operating Cash Flow
35.9M
↓ 12.88%
Investing Cash Flow
-184.5M
↓ 12.47%
Financing Cash Flow
-8.7M
↓ 102.85%
FY19Y/Y Change
Operating Cash Flow
98.4M
↑ 174.1%
Investing Cash Flow
-73.6M
↓ 60.11%
Financing Cash Flow
73.5M
↓ 948.24%
FY20Y/Y Change
Operating Cash Flow
84.0M
↓ 14.63%
Investing Cash Flow
14.0M
↓ 119.02%
Financing Cash Flow
605.5M
↑ 723.81%
FY21Y/Y Change
Operating Cash Flow
-68.1M
↓ 181.07%
Investing Cash Flow
-82.7M
↓ 690.71%
Financing Cash Flow
40.7M
↓ 93.28%
FY22Y/Y Change
Operating Cash Flow
119.0M
↓ 274.74%
Investing Cash Flow
-191.1M
↑ 131.08%
Financing Cash Flow
-40.3M
↓ 199.02%
Q3 FY22Q/Q Change
Operating Cash Flow
56.7M
↑ 124.11%
Investing Cash Flow
-33.9M
↑ 54.79%
Financing Cash Flow
-3.9M
↑ 143.75%
Q4 FY22Q/Q Change
Operating Cash Flow
50.7M
↓ 10.58%
Investing Cash Flow
-88.4M
↑ 160.77%
Financing Cash Flow
-14.5M
↑ 271.79%
Q1 FY23Q/Q Change
Operating Cash Flow
500.0K
↓ 99.01%
Investing Cash Flow
-42.1M
↓ 52.38%
Financing Cash Flow
-12.1M
↓ 16.55%
Q2 FY23Q/Q Change
Operating Cash Flow
44.0M
↑ 8700.0%
Investing Cash Flow
-23.1M
↓ 45.13%
Financing Cash Flow
3.2M
↓ 126.45%

Technicals Summary

Sell

Neutral

Buy

Insulet Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Insulet Corporation
Insulet Corporation
-0.2%
11.85%
-48.42%
-44.36%
97.6%
Stryker Corporation
Stryker Corporation
-6.65%
24.32%
8.49%
22.73%
75.27%
Boston Scientific Corp.
Boston Scientific Corp.
1.08%
35.69%
32.49%
59.19%
89.52%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.66%
25.94%
-2.06%
-10.76%
44.15%
Abbott Laboratories
Abbott Laboratories
-2.67%
11.79%
-3.02%
-13.17%
40.7%
Medtronic Plc
Medtronic Plc
-3.21%
11.3%
-10.17%
-38.59%
-5.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Insulet Corporation
Insulet Corporation
56.55
56.55
3.15
2.99
0.34
0.06
NA
10.48
Stryker Corporation
Stryker Corporation
39.35
39.35
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
62.93
62.93
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.81
37.81
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.42
33.42
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.14
25.14
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Insulet Corporation
Insulet Corporation
Buy
$11.6B
97.6%
56.55
12.16%
Stryker Corporation
Stryker Corporation
Buy
$123.8B
75.27%
39.35
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$99.0B
89.52%
62.93
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.3B
44.15%
37.81
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$186.2B
40.7%
33.42
13.96%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-5.32%
25.14
13.0%

Institutional Holdings

  • Capital Research Global Investors

    13.53%

  • Vanguard Group Inc

    11.47%

  • BlackRock Inc

    8.72%

  • FMR Inc

    8.39%

  • Wellington Management Company LLP

    4.64%

  • State Street Corporation

    4.12%

Company Information

insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down

Organization
Insulet Corporation
Employees
3000
CEO
Dr. James R. Hollingshead Ph.D.
Industry
Health Technology

Discover More

FAQs